| Efficacy of tocilizumab in patients hospitalized with Covid-19 JH Stone, MJ Frigault, NJ Serling-Boyd, AD Fernandes, L Harvey, ... New England Journal of Medicine 383 (24), 2333-2344, 2020 | 1471 | 2020 |
| Management of immunotherapy-related toxicities, version 1.2019, NCCN clinical practice guidelines in oncology JA Thompson, BJ Schneider, J Brahmer, S Andrews, P Armand, S Bhatia, ... Journal of the National Comprehensive Cancer Network 17 (3), 255-289, 2019 | 489 | 2019 |
| Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis P Domingo, I Mur, GM Mateo, M del Mar Gutierrez, V Pomar, N de Benito, ... Jama 326 (6), 499-518, 2021 | 470 | 2021 |
| ICOS-based chimeric antigen receptors program bipolar TH17/TH1 cells S Guedan, X Chen, A Madar, C Carpenito, SE McGettigan, MJ Frigault, ... Blood, The Journal of the American Society of Hematology 124 (7), 1070-1080, 2014 | 419 | 2014 |
| CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity BD Choi, X Yu, AP Castano, AA Bouffard, A Schmidts, RC Larson, ... Nature biotechnology 37 (9), 1049-1058, 2019 | 409 | 2019 |
| NCCN guidelines insights: management of immunotherapy-related toxicities, version 1.2020: featured updates to the NCCN guidelines JA Thompson, BJ Schneider, J Brahmer, S Andrews, P Armand, S Bhatia, ... Journal of the National Comprehensive Cancer Network 18 (3), 230-241, 2020 | 354 | 2020 |
| Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma MC Pasquini, ZH Hu, K Curran, T Laetsch, F Locke, R Rouce, ... Blood advances 4 (21), 5414-5424, 2020 | 329 | 2020 |
| Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells MJ Frigault, J Lee, MC Basil, C Carpenito, S Motohashi, J Scholler, ... Cancer immunology research 3 (4), 356-367, 2015 | 310 | 2015 |
| Cardiovascular events among adults treated with chimeric antigen receptor T-cells (CAR-T) RM Alvi, MJ Frigault, MG Fradley, MD Jain, SS Mahmood, M Awadalla, ... Journal of the American College of Cardiology 74 (25), 3099-3108, 2019 | 262 | 2019 |
| Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies R Benjamin, C Graham, D Yallop, A Jozwik, OC Mirci-Danicar, G Lucchini, ... The Lancet 396 (10266), 1885-1894, 2020 | 259 | 2020 |
| Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity CA Jacobson, BD Hunter, R Redd, SJ Rodig, PH Chen, K Wright, ... Journal of Clinical Oncology 38 (27), 3095, 2020 | 259 | 2020 |
| Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells P Karschnia, JT Jordan, DA Forst, IC Arrillaga-Romany, TT Batchelor, ... Blood, The Journal of the American Society of Hematology 133 (20), 2212-2221, 2019 | 244 | 2019 |
| CRISPR-Cas9 disruption of PD-1 enhances activity of universal EGFRvIII CAR T cells in a preclinical model of human glioblastoma BD Choi, X Yu, AP Castano, H Darr, DB Henderson, AA Bouffard, ... Journal for immunotherapy of cancer 7, 1-8, 2019 | 243 | 2019 |
| Tisagenlecleucel CAR T-cell therapy in secondary CNS lymphoma MJ Frigault, J Dietrich, M Martinez-Lage, M Leick, BD Choi, Z DeFilipp, ... Blood, The Journal of the American Society of Hematology 134 (11), 860-866, 2019 | 214 | 2019 |
| Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events MV Maus, S Alexander, MR Bishop, JN Brudno, C Callahan, ML Davila, ... Journal for immunotherapy of cancer 8 (2), 2020 | 184 | 2020 |
| Anti-CD37 chimeric antigen receptor T cells are active against B-and T-cell lymphomas I Scarfò, M Ormhøj, MJ Frigault, AP Castano, S Lorrey, AA Bouffard, ... Blood, The Journal of the American Society of Hematology 132 (14), 1495-1506, 2018 | 120 | 2018 |
| Axicabtagene ciloleucel in the real world: outcomes and predictors of response, resistance and toxicity CA Jacobson, B Hunter, P Armand, Y Kamihara, J Ritz, SJ Rodig, ... Blood 132, 92, 2018 | 104 | 2018 |
| Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma NJ Haradhvala, MB Leick, K Maurer, SH Gohil, RC Larson, N Yao, ... Nature medicine 28 (9), 1848-1859, 2022 | 98 | 2022 |
| State of the art in CAR T cell therapy for CD19+ B cell malignancies MJ Frigault, MV Maus The Journal of Clinical Investigation 130 (4), 1586-1594, 2020 | 96 | 2020 |
| Rational design of a trimeric APRIL-based CAR-binding domain enables efficient targeting of multiple myeloma A Schmidts, M Ormhøj, BD Choi, AO Taylor, AA Bouffard, I Scarfò, ... Blood Advances 3 (21), 3248-3260, 2019 | 91 | 2019 |
Marcela V MausHarvard Medical SchoolDirección de correo verificada de mgh.harvard.edu
